TheEdgeResearch
Home / Stocks / BLAC

Bellevue Life Sciences Acquisition Corp. (BLAC)

NASDAQ Financial Services Shell Companies
$3.01 ▼ -55.27%
Market Cap
$7.0M
Sector
Financial Services
Industry
Shell Companies
Beta
0.53
52-Wk Range
3.01-13.4
CEO
Kuk Hyoun Hwang
Country
US
Currency
USD

Bellevue Life Sciences Acquisition Corp. operates in the Shell Companies industry of the Financial Services sector, headquartered in Bellevue, WA, US. The stock last traded at $3.01, down 55.27% on the session, giving a market capitalisation of $7.0M. On trailing twelve-month figures it carries a trailing P/E of 1.23, a net margin of 301.5%. Its beta of 0.53 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
1.23
Price / Sales
2.66
Price / Book
0.11
EV / EBITDA
-0.51
Gross margin
22.2%
Operating margin
-726.1%
Net margin
301.5%
Return on equity
Debt / equity
0.00
Current ratio
0.16
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
IPO date
2023-03-21
Headquarters
Bellevue, WA, US
About Bellevue Life Sciences Acquisition Corp.

Bellevue Life Sciences Acquisition Corp. currently does not engage in substantial operational activities. Its core mission is to orchestrate a business combination, which could manifest as a merger, share exchange, asset acquisition, stock purchase, recapitalization, or reorganization, with one or more enterprises or organizations within the healthcare domain. This firm, established in 2020, maintains its principal office in Bellevue, Washington, and operates as a subordinate entity of Bellevue Global Life Sciences Investors LLC.

Comparable companies

Bellevue Life Sciences Acquisition Corp. is most often compared with the following Financial Services names:

ATIFBNIXBRLICETUEONRJVSARFACSFES
More research on BLAC
BLAC technical analysis BLAC TheEdge Score Compare against peers
Open full interactive analysis & DCF →